# Novel Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/novel-medical

- Industry: Medical Devices & Equipment
- Headquarters: Chengdu, China
- Website: www.novelmedical.cn
- Latest round: Series B (Dec 19, 2025)
- Investors on record: 5

## About

Based in Chengdu, China and established in 2011, Chengdu Novel Medical Equipment Ltd., trading as Novel Medical, is a nuclear medicine equipment manufacturer that focuses on the production and sales of nuclear radiation diagnostic and monitoring equipment and related software. The company is headquartered in Chengdu and has a joint R&D center for molecular imaging within Tsinghua University. It has a branch office in Beijing and a production base in Suzhou. It owns more than 300 intellectual property rights, including 4 international invention patents, and has been awarded as a National High-tech Enterprise, as well as the Beijing Specialized, Refined, Featured and Original SMEs. The company's medical image processing software acquires Class II medical device registration certificate. In December 2025, Novel Medical raised a series B funding from new investors Sichuan Science and Technology Innovation Investment, China Capital Management, Wise Road Capital, Jiaozi Industrial Fund, BIO-TOWN Capital, Nuts Ventures and other investors.

The company has developed coded imaging technology and panoramic imaging technology. The company's main products are medical imaging and nuclear radiation monitoring equipment. The company's products can be categorized into clinical molecular imaging product line, preclinical molecular imaging product line and nuclear security product line. Products within include X-ray biological irradiator, radioactive material image localization system, animal CT (computed tomography), etc. The company's products and systems are widely used in customs, nuclear power and medical fields.

The company generates revenue by providing medical imaging and nuclear radiation monitoring equipment and related software.

The company will use the latest funding for new product development, technology upgrades, capacity expansion, and global market expansion.

## Funding rounds

- Series B, Dec 19, 2025 — Wise Road Capital, China Capital Management, Nuts Ventures, BIO-TOWN Capital
- Series A, Jun 27, 2024 — Chengdu Science and Technology Venture Capital Group

## Investors

- Chengdu Science and Technology Venture Capital Group (https://capitalatlas.ai/funds/chengdu-science-and-technology-venture-capital-group) — Series A
- Wise Road Capital (https://capitalatlas.ai/funds/wise-road-capital) — Series B
- China Capital Management (https://capitalatlas.ai/funds/china-capital-management) — Series B
- Nuts Ventures (https://capitalatlas.ai/funds/nuts-ventures) — Series B
- BIO-TOWN Capital (https://capitalatlas.ai/funds/bio-town-capital) — Series B